Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertrand Mennecier

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2022
Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohortSimon Baldacci, Benjamin Besse, Virginie Avrillon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2020
Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE TrialJulien Mazieres, Fabrice Barlesi, Isabelle Rouquette, et al.
The Lancet. Oncology|February 24, 2015
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialNaiyer A Rizvi, Julien Mazières, David Planchard, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2022
Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohortSimon Baldacci, Benjamin Besse, Virginie Avrillon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2020
Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE TrialJulien Mazieres, Fabrice Barlesi, Isabelle Rouquette, et al.
The Lancet. Oncology|February 24, 2015
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialNaiyer A Rizvi, Julien Mazières, David Planchard, et al.
Pageof 5